Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Technology Times New Jersey.
Press releases published on June 20, 2025
PAIRMiners baut globale Cloud-Mining-Dienste aus, da XRP- und DOGE-Investoren nach Stabilität suchen
GlobeNewswire
·
June 20, 2025
Die Plattform unterstützt automatische tägliche Auszahlungen und Mining in mehreren Währungen in über 180 Ländern Bild von PAIRMiner BERLIN, June 20, 2025 (GLOBE NEWSWIRE) -- Angesichts der anhaltenden Volatilität auf dem Kryptomarkt wenden sich Anleger, …
VdoCipher Blocks Over 250,000 Video Piracy Attempts in Just 12 Months with New Detection Engine
GlobeNewswire
·
June 20, 2025
GURUGRAM, India, June 20, 2025 (GLOBE NEWSWIRE) -- In a significant step toward securing online video content, VdoCipher has announced the success of its newly deployed Pirate Detection Engine, which has blocked over 250,000 piracy attempts in just the …
NurExone Advances U.S. Growth Strategy with Acceptance into Prestigious ARMI HealthTech Hub Accelerator and Provides Corporate Update
GlobeNewswire
·
June 20, 2025
TORONTO and HAIFA, Israel, June 20, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biotech company developing exosome-based therapies for central nervous system injuries, announced …
Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)
GlobeNewswire
·
June 20, 2025
Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo in adults with BP BP is a chronic, debilitating and relapsing rare skin disease affecting …
Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid
GlobeNewswire
·
June 20, 2025
Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo …
Communiqué de presse : Dupixent est approuvé aux États-Unis comme le seul médicament ciblé pour traiter les patients atteints de pemphigoïde bulleuse
GlobeNewswire
·
June 20, 2025
Dupixent est approuvé aux États-Unis comme le seul médicament ciblé pour traiter les patients atteints de pemphigoïde bulleuse L’approbation est basée sur des résultats pivots montrant des améliorations de la rémission durable de la maladie et une …
Translr App Announces New Strategies to Help Reduce Gender Disclosure Anxiety for Transgender Users
GlobeNewswire
·
June 20, 2025
New York, New York, June 19, 2025 (GLOBE NEWSWIRE) -- As debates around gender history disclosure continue to spark controversy in public discourse and on mainstream dating platforms, Translr announces new strategies aimed at reducing gender disclosure …
Telix Theranostic Programs and Satellite Symposia on Innovation in PSMA and CAIX Imaging Featured at SNMMI 2025
GlobeNewswire
·
June 20, 2025
MELBOURNE, Australia and INDIANAPOLIS, June 20, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”, “the Company”) today announces five abstract presentations and two satellite symposia featuring its developmental …